Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.

CAS  PubMed  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

CAS  PubMed  PubMed Central  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

PubMed  Google Scholar 

Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108(1):110–21.

CAS  PubMed  Google Scholar 

Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28(10):669–76.

CAS  PubMed  PubMed Central  Google Scholar 

Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, et al. Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and Lisocabtagene maraleucel. Blood Adv. 2024;8(20):5346–54.

CAS  PubMed  PubMed Central  Google Scholar 

Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CS, Bücklein VL, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7(11):2436–48.

CAS  PubMed  PubMed Central  Google Scholar 

Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–54.

CAS  PubMed  PubMed Central  Google Scholar 

Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, Tresckow BV, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349–58.

CAS  PubMed  Google Scholar 

Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, et al. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leuk Lymphoma. 2022;63(9):2052–62.

PubMed  Google Scholar 

Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28(7):404.e1-e6.

CAS  PubMed  Google Scholar 

Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31(1):1–11.

PubMed  PubMed Central  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38.

CAS  PubMed  Google Scholar 

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259–75.

CAS  PubMed  Google Scholar 

Passweg JR, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. 2024;59(6):803–12.

CAS  PubMed  PubMed Central  Google Scholar 

Spellman ST, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy – a report from the CIBMTR. Transplant Cell Ther. 2025;31(8):505–532

PubMed  Google Scholar 

Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma—the UK real-world experience. Br J Haematol. 2022;198(3):492–502.

CAS  PubMed  Google Scholar 

Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailen R, Corral LL, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10(10):3214–23.

CAS  PubMed  PubMed Central  Google Scholar 

Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95(11):1324–33.

CAS  PubMed  Google Scholar 

Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, et al. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol. 2023;28(6):816–26.

CAS  PubMed  Google Scholar 

Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–24.

CAS  PubMed  PubMed Central  Google Scholar 

Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial Tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40(9):945–55.

CAS  PubMed  Google Scholar 

Kato I, Tomizawa D, Kato M, Hirabayashi S, Manabe A, Irie M, et al. Real-world outcomes of commercial Tisagenlecleucel for children, adolescents, and young adults with acute lymphoblastic leukemia in Japan. Transplant Cell Ther. 2025;31(2):86–96.

PubMed  Google Scholar 

Beyar-Katz O, Kikozashvili N, Bar On Y, Amit O, Perry C, Avivi I, et al. Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. Eur J Haematol. 2022;108(1):52–60.

CAS  PubMed  Google Scholar 

Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam SK, et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024;30(10):955–69.

CAS  PubMed  Google Scholar 

Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108(2):615–20.

PubMed  Google Scholar